# Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

> **NCT02477696** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Acerta Pharma BV** · enrollment: 533 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT02477696
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-07-28
- **Primary completion:** 2020-09-15
- **Final completion:** 2028-01-03
- **Target enrollment:** 533 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02477696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02477696, "Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02477696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*